![Assay: Irreversible inhibition of rat brain cytosolic MAGL assessed as [3H] - EMBL-EBI](https://cedclinic.com/wp-content/uploads/2026/06/ced-pexels-4226264-1-150x150.jpg "Assay: Irreversible inhibition of rat brain cytosolic MAGL assessed as [3H] - EMBL-EBI 17")
GLP-1 Receptor Agonist Clinical Evidence and Results
GLP-1 Clinical Relevance #50Moderate Clinical Relevance Relevant context for GLP-1 prescribers; interpret with care. ⚕ GLP-1 News | CED Clinic Clinical CommentaryGLP-1 Receptor AgonistWeight LossSemaglutidePrimary CareAdults with…
GLP-1 Gene Therapy Clinical Trials: Latest Research
GLP-1 Clinical Relevance #45Moderate Clinical Relevance Relevant context for GLP-1 prescribers; interpret with care. ⚕ GLP-1 News | CED Clinic Clinical TrialGene TherapyType 2 DiabetesGLP-1 Gene TherapyEndocrinologyAdults with…
GLP-1 Receptor Agonists: Clinical Evidence and CV Outcomes
GLP-1 Clinical Relevance #48Moderate Clinical Relevance Relevant context for GLP-1 prescribers; interpret with care. ⚕ GLP-1 News | CED Clinic Clinical TrialRandomized Controlled TrialType 2 DiabetesSemaglutideEndocrinologyAdults…
Semaglutide vs Tirzepatide: Clinical Differences
GLP-1 Clinical Relevance #43Contextual Information Background context; limited direct clinical applicability. ⚕ GLP-1 News | CED Clinic Clinical ReviewComparative StudyType 2 DiabetesTirzepatideEndocrinologyAdults With…
Can Epigenetic Therapies Break the Vicious Cycle Between Gum Disease and Diabetes?
Periodontitis affects 45% of young adults, with the incidence reaching 60% in those aged over 65, and is considered the sixth major consequence of DM. Patients with periodontitis have a 33% increased risk of hyperglycemia and a 1.24 times higher risk of…
Glucagon-like peptide-1 receptor agonists and risk of substance use disorders among US veterans with type 2 diabetes: cohort study.
A large cohort study of US veterans found GLP-1 receptor agonists substance use disorder prevention benefits compared to other diabetes medications. This BMJ research suggests potential neurobiological effects beyond metabolic control, though causation…
CBD Gummies for Diabetes: What the Evidence Shows and How to Approach Them
✦ New CED Clinical Relevance #70Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News | CED Clinic DiabetesCbdEndocannabinoidBlood…
GLP-1 Drugs: Obesity & Diabetes Treatment Evidence 2026
GLP-1 Clinical Relevance #46Moderate Clinical Relevance Relevant context for GLP-1 prescribers; interpret with care. ⚕ GLP-1 News | CED Clinic Clinical NewsObservational StudyObesity and DiabetesGLP-1 Receptor…
Modulation of High Glucose-induced Oxidative Stress Using Cannabis sativa Plant Extracts …
✦ New CED Clinical Relevance #70Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News | CED Clinic DiabetesOxidative…
GLP-1 Receptor Agonist Guidance: What the WHO Data Shows
GLP-1 Clinical Relevance #42Contextual Information Background context; limited direct clinical applicability. ⚕ GLP-1 News | CED Clinic NewsObservationalObesityGLP-1 Receptor AgonistPublic Health PolicyAdults with ObesityWeight…